Wang, R.-F. & Rosenberg, S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85–100 (1999).
Boon, T. & Van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725–729 (1996).
Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999).
Houghton, A.N., Gold, J.S. & Blachere, N.E. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13, 134–140 (2001).
Dallal, R.M. & Lotze, M.T. The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 12, 583–588 (2000).
Schuler, G. & Steinman, R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183–1187 (1997).
Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T. & Falo, L.D., Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–287 (1996).
Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).
Young, J.W. & Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183, 7–11 (1996).
Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328–332 (1998).
Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669–1678 (1999).
Bellone, M. et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165, 2651–2656 (2000).
Schreurs, M.W. et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 60, 6995–7001 (2000).
Parkhurst, M.R. et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J. Immunol. 157, 2539–2548 (1996).
Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321–327 (1998).
Slansky, J.E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC–peptide–TCR complex. Immunity 13, 529–538 (2000).
Labeur, M.S. et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168–175 (1999).
Cella, M., Engering, A., Pinet, V., Pieters, J. & Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782–787 (1997).
Ludewig, B., Odermatt, B., Ochsenbein, A.F., Zinkernagel, R.M. & Hengartner, H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol. Rev. 169, 45–54 (1999).
Frankel, A.D. & Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193 (1988).
Elliott, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223–233 (1997).
Phelan, A., Elliott, G. & O'Hare, P. Intercellular delivery of functional p53 by the herpesvirus protein VP22 [see comments]. Nat. Biotechnol. 16, 440–443 (1998).
Lin, Y.Z., Yao, S.Y., Veach, R.A., Torgerson, T.R. & Hawiger, J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270, 14255–14258 (1995).
Rojas, M., Donahue, J.P., Tan, Z. & Lin, Y.Z. Genetic engineering of proteins with cell membrane permeability. Nat. Biotechnol. 16, 370–375 (1998).
Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664–668 (1994).
Kim, D.T. et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159, 1666–1668 (1997).
Schwarze, S.R., Ho, A., Vocero-Akbani, A. & Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572 (1999).
Lindgren, M., Hallbrink, M., Prochiantz, A. & Langel, U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21, 99–103 (2000).
Caron, N.J. et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol. Ther. 3, 310–318 (2001).
Wang, R.-F., Appella, E., Kawakami, Y., Kang, X. & Rosenberg, S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207–2216 (1996).
Bloom, M.B. et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–460 (1997).
Parkhurst, M.R. et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895–4901 (1998).
Zeh, H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A. & Yang, J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989–994 (1999).
Overwijk, W.W. et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982–2987 (1999).
Bowne, W.B. et al. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190, 1717–1722 (1999).
Winzler, C. et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J. Exp. Med.185, 317–328 (1997).
Srivastava, P.K. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1, 363–366 (2000).
Suhrbier, A. et al. Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J. Immunol. 150, 2169–2178 (1993).
Casares, N. et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur. J. Immunol. 31, 1780–1789 (2001).
Wang, R.-F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22, 269–276 (2001).
Greenberg, P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281–355 (1991).
Pardoll, D.M. & Topalian, S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588–594 (1998).
Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
Toes, R.E., Ossendorp, F., Offringa, R. & Melief, C.J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753–756 (1999).
Specht, J.M. et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213–1221 (1997).